Inactive Instrument

All News Tiziana Life Sciences PLC London S.E.

Equities

GB00B28XMY25

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program	Apr. 25	PU
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	Apr. 25	AQ
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23	MT
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	Apr. 23	MT
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23	AQ
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23	CI
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today	Apr. 22	AQ
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program	Apr. 22	AQ
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	Apr. 22	CI
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 19	AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®	Apr. 19	AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	Apr. 19	CI
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 18	CI
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 11	AQ
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease	Mar. 05	AQ
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	AQ
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	Jan. 05	MT
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024	Jan. 05	AQ
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Tiziana Life Sciences PLC London S.E.

Equities

GB00B28XMY25

All News

Filters